<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01258439</url>
  </required_header>
  <id_info>
    <org_study_id>ROaR+</org_study_id>
    <nct_id>NCT01258439</nct_id>
  </id_info>
  <brief_title>Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.</brief_title>
  <acronym>ROaR+</acronym>
  <official_title>Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir-boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)-Naive Adults or Adults Recommencing ART.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St Vincent's Hospital, Sydney</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St Vincent's Hospital, Sydney</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study into the effects of three drugs used to treat HIV infection. Some
      drugs used to treat HIV have been associated with changes in blood fats such as cholesterol
      that could be harmful over the long-term, because these blood fat changes have been
      associated with a small, increased risk of heart disease and stroke in some studies of adults
      with HIV. Now that HIV can be controlled for long periods in most patients, and because heart
      disease is one of the biggest causes of illness and death in the general population, it is
      important to develop new HIV treatments that control HIV effectively but do not cause
      abnormal blood fats.

      Hypothesis: That Raltegravir will result in less post-prandial lipid disturbances than
      ritonavir-boosted darunavir.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the effects of ritonavir plus darunavir daily to raltegravir twice daily on post prandial lipid responses over 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>Fasting samples will be taken for total cholesterol, LDL and HDL cholesterol, and triglycerides. Repeat lipid samples will be collected before a high fat meal is consumed. After the meal is completed , blood will be collected at 1, 2, 3, and 4 hours at baseline, week 4 and week 24 visits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>24 weeks</time_frame>
    <description>Safety parameters will be assessed by measurement of urea and electrolytes, LFTs, urine protein to creatinine ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other metabolic parameters</measure>
    <time_frame>24 weeks</time_frame>
    <description>Fasting metabolic parameters will be assessed. Study staff and participants will be blinded to the results fo these tests until completion of the study or parameters become sginificantly abnormal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial stiffness</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>HIV</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>1.Raltegravir plus truvada</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Raltegravir 400mg twice daily plus truvada 300mg/200mg once daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. ritonavir boosted darunavir plus truvada</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Darunavir 800mg with ritonavir 100mg plus truvada 300mg/200mg once daily for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir plus truvada</intervention_name>
    <description>raltegravir 400 mg tablet with truvada 300/200 mg tablet for 24 weeks</description>
    <arm_group_label>2. ritonavir boosted darunavir plus truvada</arm_group_label>
    <other_name>tenofovir disoproxil fumarate</other_name>
    <other_name>Isentress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir, ritonavir, tenofovir/emtricitabine (Truvada)</intervention_name>
    <description>Darunavir two 400mg tablets with one ritonavir 100mg capsule once daily plus Tenofovir/emtricitabine (Truvada) one 300mg/200mg tablet once daily with food for 24 weeks</description>
    <arm_group_label>1.Raltegravir plus truvada</arm_group_label>
    <other_name>Prezista</other_name>
    <other_name>Norvir</other_name>
    <other_name>Tenofovir/emtricitabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed, informed consent

          -  Age &gt;18 years

          -  HIV infection documented by HIV antibody test and Western Blot prior to study entry

          -  No previous ART OR no ART for 6 months prior to randomisation

          -  CD4+ count of &lt;500 cells/mm or viral load &gt;10,000 copies/ml within 60 days prior to
             randomisation

          -  No genotypic resistance to Raltegravir, Tenofovir/emtricitabine, Darunavir, Ritonavir

          -  Body mass index less than 30kg/m2

        Exclusion Criteria:

          -  Primary HIV infection within the last 6 months

          -  Active infection or opportunistic illness within the previous 30 days

          -  Use of any medication contra-indicated with ritonavir-boosted darunavir or raltegravir

          -  Use of lipid-lowering therapy

          -  Diabetes mellitus (fasting glucose &gt;7.0mml/l or a prior diagnosis of diabetes)

          -  Use of oral prednisolone &gt; 7.5mg daily or equivalent

          -  pregnancy or Breast feeding

          -  proven hypersensitivity to one or more components of the study meal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew D Carr, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Vincent's Hospital, Sydney, Australia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Holdsworth House Medical Practice</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent Hospital, Clinical Research Program</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2010</study_first_submitted>
  <study_first_submitted_qc>December 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2010</study_first_posted>
  <last_update_submitted>January 8, 2015</last_update_submitted>
  <last_update_submitted_qc>January 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St Vincent's Hospital, Sydney</investigator_affiliation>
    <investigator_full_name>Andrew Carr</investigator_full_name>
    <investigator_title>Head, Clinical Research Program</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>post prandial lipids</keyword>
  <keyword>ritonavir</keyword>
  <keyword>darunavir</keyword>
  <keyword>raltegravir</keyword>
  <keyword>arterial stiffness</keyword>
  <keyword>tonometry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

